Elipovimab (GS-9722) is a humanized broadly neutralizing antibody (bNAb) targeting the V3 glycan supersite of the HIV-1 envelope glycoprotein gp120. As an Fc-optimized version of PGT121, it neutralizes viral particles and eliminates infected cells via antibody-dependent cellular cytotoxicity (ADCC). The antibody exhibits enhanced effector cell-mediated killing activity in the presence of TLR agonists.
CAS Nummer:
[2101210-43-7]
Target-Kategorie:
HIV Protease
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
